TIDMEKF

RNS Number : 8308X

EKF Diagnostics Holdings PLC

01 September 2022

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Notice of Interim Results & Investor Presentation

Notice of Results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , confirms that the Company will announce its interim results for the six months ended 30 June 2022 on Tuesday 20 September 2022.

Investor Presentation

Mike Salter, Chief Executive Officer, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30 pm on Tuesday 20 September 2022. The presentation is open to all existing and potential investors.

Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

 
EKF Diagnostics Holdings plc                                       www.ekfdiagnostics.com 
Mike Salter, CEO / Marc Davies, CFO                              Tel: +44 (0)29 2071 0570 
 
Singer Capital Markets (Nominated Adviser                        Tel: +44 (0)20 7496 3000 
 & Joint Broker) 
Aubrey Powell / George Tzimas 
 
Investec Bank plc (Joint Broker)                                 Tel: +44 (0)20 7597 4000 
Gary Clarence / Daniel Adams / Ben Farrow 
 
Walbrook PR Limited                        Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com 
Paul McManus / Lianne Applegarth                           Mob: +44 (0)7980 541 893 / +44 
                                                                          (0)7584 391 303 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 
 Point-of-Care            Providing a portfolio of Point-of-Care analysers and 
                           consumables, particularly for use in the area of Hematology 
                           and Diabetes, for use in hospital and research laboratories, 
                           doctor's offices, blood banks and for in-field anaemia 
                           screening programmes. EKF has an estimated 80,000 
                           hemoglobin, hematocrit, HbA1c, glucose and lactate 
                           analysers in regular use across more than 100 countries. 
 Central Laboratory       Clinical chemistry, Small lab analysers, Centrifuges 
                           Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated 
                           Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin 
 Life Sciences            Enzyme fermentation, Custom products and Bulk fermentation 
 Contract Manufacturing   Bulk formulation, Sample collection kits, Private 
                           labelling, Molecular and forensic kits 
 Laboratory Services      In September 2021, EKF completed the acquisition of 
                           Advanced Diagnostic Laboratory LLC ("ADL Health"), 
                           a Texas based testing laboratory certified under the 
                           Clinical Laboratory Improvement Amendments ("CLIA") 
                           for high complexity testing. The laboratory provides 
                           testing for a variety of clinical, forensic and microbiological 
                           sample types using a range of analytical techniques. 
                           This acquisition positions EKF as a leading 'one stop' 
                           provider of diagnostic products and services from 
                           sample collection to results. 
 

EKF's growth strategy to 2024 and beyond can be summarised as:

 
 --   continuing innovation in products and services in Point-of-Care, 
       Central Laboratory and Life Sciences leveraging new and existing 
       routes to market and relationships; 
 --   investment in expanded production and kitting capabilities to offer 
       a suite of diagnostic Contract Manufacturing solutions to third 
       party businesses; 
 --   expansion of CLIA Laboratories Testing offering, building on the 
       acquired capabilities in ADL Health; and 
 --   concluding complementary earnings-enhancing acquisitions with key 
       strategic value. 
 

EKF will also continue to generate enhanced shareholder value through:

 
 --   a progressive dividend policy; and 
 --   its agreement with Mount Sinai Innovation Partners ("MSIP"), which 
       allows us advanced access to innovative commercial opportunities 
       such as those already seen with Renalytix plc, Verici Dx plc and 
       Trellus Health plc. 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAKPFDADAEFA

(END) Dow Jones Newswires

September 01, 2022 02:02 ET (06:02 GMT)

Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Nov 2022 a Dic 2022 Haga Click aquí para más Gráficas Ekf Diagnostics.
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Dic 2021 a Dic 2022 Haga Click aquí para más Gráficas Ekf Diagnostics.